N-Formimidoyl thienamycin was the most active drug against strains of Pseudomonas aeruginosa with a 90% minimum inhibitory concentration of 1.25 ,ug/ml. With the exception of P. maltophilia, thienamycin was as active or more active than moxalactam against other species of pseudomonads and against other genera of nonfermenters.
Moxalactam is a new beta-lactam antimicrobial agent with a broad spectrum of activity against aerobic and facultative gram-negative rods (2, 4, 5, 8, 16) . Although there are fewer reports on N-formimidoyl thienamycin, this new more stable derivative of thienamycin also has an expanded spectrum of activity (7, 14, 17) . Except for Pseudomonas aeruginosa (6, 8, 13, 15, 19 ) and a few other common Pseudomonas species (9, 11) , there are relatively few data available on the susceptibility of significant numbers of well-characterized nonfermentative gram-negative rods to these antimicrobial agents. This report is the result of an investigation of the in vitro activity of N-formimidoyl thienamycin and moxalactam against common and less commonly occurring species of nonfermenters. In addition, the susceptibility of aminoglycoside-resistant species of Pseudomonas is included.
The MICs for all antibiotics were determined simultaneously for each strain by the microdilution method. Microtiter trays containing twofold dilutions of the antibiotic in Mueller-Hinton broth supplemented with calcium (50 jig/ml) and magnesium (25 jig/ml) were inoculated with 0.05 ml of an overnight culture of the organism diluted in cation-supplemented broth to contain 2 x 105 organisms per ml. The MIC was read as the lowest concentration of the drug inhibiting visible growth of the organism after incubation at 37°C for 24 h.
The effect of inoculum size on the MIC was determined for representative organisms from each group. The inocula used ranged from 104 to 107 organisms per ml.
The results of the in vitro activity of Nformimidoyl thienamycin and moxalactam are recorded in Table 1 . These results show that the 50% MIC (MIC50) for moxalactam against P. aeruginosa was 32 ,ug/ml, whereas the MIC90 was 128 ,ug/ml. Only 19%o of the isolates was susceptible to moxalactam at 8 ,g/ml; 73% was inhibited at 32 ,g/ml. In contrast, the MIC50 for N-formimidoyl thienamycin was 0.625 ,ug/ml, and the MIC90 was 1.25 ,ug/ml. N-formimidoyl thienamycin clearly was more active than moxalactam; 90o of the isolates was inhibited at 1.25 Lg/ml.
In general, N-formimidoyl thienamycin was as active or more active than moxalactam against the other species of Pseudomonas. The MICgo for N-formimidoyl thienamycin against P. cepacia was relatively high (10 ,g/ml). P. acidovorans was equally susceptible to moxalactam and ANTIMICROB. AGENTS CHEMOTHER. The in vitro activity of moxalactam and Nformimidoyl thienamycin against aminoglycoside-resistant strains of P. aeruginosa was also tested. Organisms were divided into three groups according to their pattern of resistance: resistance to gentamicin alone, to gentamicin and tobramycin, and to gentamicin, tobramycin, and amikacin. Aminoglycoside resistance is defined as -8 ,g/ml for gentamicin and tobramycin and .32 ,ug/ml for amikacin. The MIC90 for moxalactam and N-formimidoyl thienamycin against each of three groups of aminoglycosideresistant isolates were 128 and 1.25 pg/ml, respectively. These results are similar to those of the aminoglycoside-sensitive strains.
Our results indicate that the MIC90 for moxalactam against P. aeruginosa is relatively high (3, 18) , who showed an increase in MICs at high inocula of t07 organisms per ml. Our data show that this inoculum effect also is seen for most other species when tested with moxalactam. The inoculum effect is clearly less evident when N-formimidoyl theinamycin is tested.
